NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

May 19, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer
Marianne Andreach
Vice President, Strategic Marketing & Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

May 7, 2014
Tim Mayleben
President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the recent spate of biotech IPOs belies the earlier struggle to finance trials and product development. I was joined by fellow biotech CEOs, Jeff Abbey of Argos and Scott Koenig of MacroGenics, for an engaging and… Read More

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

April 21, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment… Read More

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

December 31, 2013
Tim Mayleben
President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule,… Read More

Posted In: Company News

Going with Your Gut

August 30, 2013
Roger Newton, Ph.D., F.A.H.A.
Executive Chairman and Chief Scientific Officer

Sometimes in science, you have to go with your gut. Years ago, my gut instinct told me that a drug I was working on would be successful, even though it was still early in development and several effective competitors were already on the market. I believed in this drug so much that I begged the… Read More

Getting the Band Back Together

August 8, 2013
Tim Mayleben
President and Chief Executive Officer

Late last year, one of the country’s most brilliant scientists called me and asked if I wanted to help him change the lives of millions of people – again. Two decades ago, that scientist, Roger Newton, helped create the statin Lipitor, which turned out to be the best selling pharmaceutical drug of all time. Because… Read More